JP2016515582A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515582A5
JP2016515582A5 JP2016505551A JP2016505551A JP2016515582A5 JP 2016515582 A5 JP2016515582 A5 JP 2016515582A5 JP 2016505551 A JP2016505551 A JP 2016505551A JP 2016505551 A JP2016505551 A JP 2016505551A JP 2016515582 A5 JP2016515582 A5 JP 2016515582A5
Authority
JP
Japan
Prior art keywords
pyrazol
pyridin
carbonyl
hydroxy
methylbenzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016505551A
Other languages
English (en)
Japanese (ja)
Other versions
JP6282724B2 (ja
JP2016515582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/031918 external-priority patent/WO2014160810A1/en
Publication of JP2016515582A publication Critical patent/JP2016515582A/ja
Publication of JP2016515582A5 publication Critical patent/JP2016515582A5/ja
Application granted granted Critical
Publication of JP6282724B2 publication Critical patent/JP6282724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016505551A 2013-03-29 2014-03-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用 Active JP6282724B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361806806P 2013-03-29 2013-03-29
US61/806,806 2013-03-29
US201361916715P 2013-12-16 2013-12-16
US61/916,715 2013-12-16
PCT/US2014/031918 WO2014160810A1 (en) 2013-03-29 2014-03-26 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009987A Division JP6462911B2 (ja) 2013-03-29 2018-01-24 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2016515582A JP2016515582A (ja) 2016-05-30
JP2016515582A5 true JP2016515582A5 (OSRAM) 2017-05-18
JP6282724B2 JP6282724B2 (ja) 2018-02-21

Family

ID=50792544

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016505551A Active JP6282724B2 (ja) 2013-03-29 2014-03-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018009987A Active JP6462911B2 (ja) 2013-03-29 2018-01-24 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018245492A Active JP6640978B2 (ja) 2013-03-29 2018-12-27 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2019235781A Active JP6874114B2 (ja) 2013-03-29 2019-12-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018009987A Active JP6462911B2 (ja) 2013-03-29 2018-01-24 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018245492A Active JP6640978B2 (ja) 2013-03-29 2018-12-27 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2019235781A Active JP6874114B2 (ja) 2013-03-29 2019-12-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用

Country Status (40)

Country Link
US (5) US9040522B2 (OSRAM)
EP (2) EP3336084B1 (OSRAM)
JP (4) JP6282724B2 (OSRAM)
KR (1) KR102376354B1 (OSRAM)
CN (1) CN105492433B (OSRAM)
AP (1) AP2015008783A0 (OSRAM)
AU (1) AU2014241183B2 (OSRAM)
BR (1) BR112015020350B1 (OSRAM)
CA (1) CA2903875C (OSRAM)
CL (1) CL2015002473A1 (OSRAM)
CR (1) CR20150517A (OSRAM)
CY (1) CY1120029T1 (OSRAM)
DK (1) DK2978752T3 (OSRAM)
EA (1) EA031647B1 (OSRAM)
EC (1) ECSP15045801A (OSRAM)
ES (1) ES2660914T3 (OSRAM)
GE (1) GEP201706761B (OSRAM)
HR (1) HRP20180341T1 (OSRAM)
HU (1) HUE038220T2 (OSRAM)
IL (1) IL240803B (OSRAM)
JO (1) JO3722B1 (OSRAM)
LT (1) LT2978752T (OSRAM)
ME (1) ME03024B (OSRAM)
MX (1) MX370388B (OSRAM)
MY (1) MY184218A (OSRAM)
PE (1) PE20151860A1 (OSRAM)
PH (1) PH12015502248B1 (OSRAM)
PL (1) PL2978752T3 (OSRAM)
PT (1) PT2978752T (OSRAM)
RS (1) RS56974B1 (OSRAM)
SG (1) SG11201506749XA (OSRAM)
SI (1) SI2978752T1 (OSRAM)
SM (1) SMT201800112T1 (OSRAM)
TN (1) TN2015000397A1 (OSRAM)
TR (1) TR201802632T4 (OSRAM)
TW (1) TWI635084B (OSRAM)
UA (1) UA118965C2 (OSRAM)
UY (1) UY35513A (OSRAM)
WO (1) WO2014160810A1 (OSRAM)
ZA (1) ZA201506484B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3336084B1 (en) 2013-03-29 2021-03-17 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
AU2015328174B2 (en) 2014-10-06 2020-05-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
JOP20190042B1 (ar) 2016-09-30 2021-08-17 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
JOP20190125B1 (ar) 2016-12-09 2022-03-14 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN107163043A (zh) * 2017-06-16 2017-09-15 上海毕得医药科技有限公司 一种吡唑并[1,5‑a]吡啶‑3‑羧酸酯衍生物的合成方法
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US11434201B2 (en) 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2019195739A1 (en) * 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020156571A1 (zh) * 2019-02-02 2020-08-06 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
CN121085893A (zh) * 2020-03-20 2025-12-09 阿克比治疗有限公司 Phd抑制剂化合物、组合物和用途
CN115605467B (zh) * 2020-03-20 2025-06-13 阿克比治疗有限公司 Phd抑制剂化合物、组合物和其用途
CN119823097A (zh) * 2020-03-20 2025-04-15 阿克比治疗有限公司 Phd抑制剂化合物、组合物和用途
TW202200134A (zh) 2020-04-20 2022-01-01 美商阿克比治療有限公司 治療病毒感染、器官損傷及相關症狀之方法
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物
JP7710897B2 (ja) * 2021-06-01 2025-07-22 三菱ガス化学ネクスト株式会社 1-アルキル-5-ヒドロキシピラゾールの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20040067955A1 (en) * 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
MX2008002063A (es) 2005-08-19 2008-04-16 Astrazeneca Ab Derivados de pirazolona para el tratamiento de tuberculosis.
EP2044005B8 (en) * 2006-06-26 2012-12-05 Warner Chilcott Company, LLC Prolyl hydroxylase inhibitors and methods of use
TWI386405B (zh) * 2006-09-05 2013-02-21 咪唑衍生物
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
NZ577719A (en) 2006-12-29 2012-06-29 Abbott Gmbh & Co Kg Pyrazol-1-yl-aryl amides and their analogues and their pharmaceutical uses
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
MX2010010209A (es) * 2008-03-18 2010-10-05 Merck Sharp & Dohme 4-hidroxipirimidina-5-carboxamidas sustituidas.
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CN102333776B (zh) * 2008-12-29 2014-05-21 赛诺菲 2-吡啶-2-基-吡唑-3(2h)-酮的衍生物、其制备和治疗用途
KR20110099786A (ko) * 2008-12-29 2011-09-08 사노피 2-피리딘-2-일-피라졸-3(2h)-온의 유도체, 그의 제조법 및 hif 활성화제로서의 치료 용도
EP3336084B1 (en) * 2013-03-29 2021-03-17 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors

Similar Documents

Publication Publication Date Title
JP2016515582A5 (OSRAM)
IL244787B (en) Polymorph c of n-((4,6-dimethyl-2 oxo-1,2-dihydropyridine-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl -4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide monohydrochloride, methods for its preparation, medical preparations containing it and its use
SI2978752T1 (en) 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD
JP2016506960A5 (OSRAM)
JP2013543896A5 (OSRAM)
JP2016040288A5 (OSRAM)
JP2016506962A5 (OSRAM)
CL2015000332A1 (es) Forma cristalina a y racemato cristalino de 1-(5'-(5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-4,5-dihidroisoxazol-3-il)-3'h-espiro[azetidin-3,1'-isobenzofuran]-1-il)-2-(metilsulfonil)etanona; procedimiento de preparacion de la forma cristalina a; composicion que la comprende; y su uso para el tratamiento de una infeccion o infestacion parasitaria.
JP2016530213A5 (OSRAM)
JP2013531031A5 (OSRAM)
JP2016505637A5 (OSRAM)
JP2017513894A5 (OSRAM)
HUE045353T2 (hu) N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)-metil)-5-(etil-(tetrahidro-2H-pirán-4-il) -amino)-4-metil-4'-(morfolino-metil)-[1,1'-bifenil]-3-karboxamid-hidrobromid a hematológiai rendszer egy sejtszaporodásos rendellenességének kezelésében való alkalmazásra
JP2012522764A5 (OSRAM)
JP2014505107A5 (OSRAM)
JP2017517538A5 (OSRAM)
JP2015524472A5 (OSRAM)
JP2019512535A5 (OSRAM)
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
MX364094B (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)-fenil]-n-metilacetamida con un intervalo de distribucion de tamaño de particula especifica y un intervalo de area superficial especifica para uso en formulaciones farmaceuticas.
JP2013540712A5 (OSRAM)
MX371088B (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)fenil]-n-metilacetamida.
JP2015516427A5 (OSRAM)
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство
JP2016523260A5 (OSRAM)